Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Inactivation of Tsc2 in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney.

Gewin LS, Summers ME, Harral JW, Gaskill CF, Khodo SN, Neelisetty S, Sullivan TM, Hopp K, Reese JJ, Klemm DJ, Kon V, Ess KC, Shi W, Majka SM.

Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1201-F1210. doi: 10.1152/ajprenal.00629.2018. Epub 2019 Aug 28.

PMID:
31461347
2.

Urinary apoAl: novel marker of renal disease?

Clark AJ, Yang H, Kon V.

Pediatr Nephrol. 2019 Nov;34(11):2425-2426. doi: 10.1007/s00467-019-04328-1. Epub 2019 Aug 11. No abstract available.

PMID:
31402404
3.

Urinary apolipoprotein AI in children with kidney disease.

Clark AJ, Jabs K, Hunley TE, Jones DP, VanDeVoorde RG, Anderson C, Du L, Zhong J, Fogo AB, Yang H, Kon V.

Pediatr Nephrol. 2019 Nov;34(11):2351-2360. doi: 10.1007/s00467-019-04289-5. Epub 2019 Jun 23.

PMID:
31230128
4.

Lipoprotein modulation of proteinuric renal injury.

Tsuchida Y, Zhong J, Otsuka T, Dikalova A, Pastan I, Anantharamaiah GM, Linton MF, Yancey PG, Ikizler TA, Fogo AB, Yang H, Kon V.

Lab Invest. 2019 Jul;99(8):1107-1116. doi: 10.1038/s41374-019-0253-6. Epub 2019 Apr 24.

5.

IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD.

Hung AM, Tsuchida Y, Nowak KL, Sarkar S, Chonchol M, Whitfield V, Salas N, Dikalova A, Yancey PG, Huang J, Linton MF, Ikizler TA, Kon V.

Clin J Am Soc Nephrol. 2019 May 7;14(5):702-711. doi: 10.2215/CJN.04360418. Epub 2019 Apr 23.

PMID:
31015261
6.

Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis.

Wiese CB, Zhong J, Xu ZQ, Zhang Y, Ramirez Solano MA, Zhu W, Linton MF, Sheng Q, Kon V, Vickers KC.

Atherosclerosis. 2019 Mar;282:121-131. doi: 10.1016/j.atherosclerosis.2019.01.023. Epub 2019 Jan 30.

PMID:
30731284
7.

Kidney as modulator and target of "good/bad" HDL.

Zhong J, Yang H, Kon V.

Pediatr Nephrol. 2019 Oct;34(10):1683-1695. doi: 10.1007/s00467-018-4104-2. Epub 2018 Oct 5. Review.

PMID:
30291429
8.

Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.

Kaseda R, Tsuchida Y, Gamboa JL, Zhong J, Zhang L, Yang H, Dikalova A, Bian A, Davies S, Fogo AF, Linton MF, Brown NJ, Ikizler TA, Kon V.

Nutr Metab Cardiovasc Dis. 2018 Jun;28(6):582-591. doi: 10.1016/j.numecd.2018.02.020. Epub 2018 Mar 8.

9.

Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism.

Kaseda R, Tsuchida Y, Yang HC, Yancey PG, Zhong J, Tao H, Bian A, Fogo AB, Linton MRF, Fazio S, Ikizler TA, Kon V.

BMC Nephrol. 2018 Jan 27;19(1):17. doi: 10.1186/s12882-018-0814-8.

10.

Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis.

Ormseth MJ, Yancey PG, Yamamoto S, Oeser AM, Gebretsadik T, Shintani A, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Raggi P, Kon V, Stein CM.

IJC Metab Endocr. 2016 Dec;13:6-11. doi: 10.1016/j.ijcme.2016.08.002. Epub 2016 Aug 28.

11.

Kidneys: key modulators of high-density lipoprotein levels and function.

Yang H, Fogo AB, Kon V.

Curr Opin Nephrol Hypertens. 2016 May;25(3):174-9. doi: 10.1097/MNH.0000000000000217. Review.

12.

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.

Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C; TETRAD Investigators.

Arthritis Rheumatol. 2016 Sep;68(9):2099-105. doi: 10.1002/art.39675.

13.

HDL: Beyond Atheroprotection.

Kon V, Linton MF.

J Am Soc Nephrol. 2016 Feb;27(2):341-4. doi: 10.1681/ASN.2015070793. Epub 2015 Aug 28. No abstract available.

14.

Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V.

Atherosclerosis. 2015 Sep;242(1):56-64. doi: 10.1016/j.atherosclerosis.2015.06.055. Epub 2015 Jul 4.

15.

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Kon V, Yang H, Fazio S.

Arch Med Res. 2015 Jul;46(5):379-91. doi: 10.1016/j.arcmed.2015.05.009. Epub 2015 May 23. Review.

16.

Dysfunctional high-density lipoproteins in children with chronic kidney disease.

Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V.

Metabolism. 2015 Feb;64(2):263-73. doi: 10.1016/j.metabol.2014.10.020. Epub 2014 Oct 25.

17.

Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Zhong J, Yang HC, Kon V, Fogo AB, Lawrence DA, Ma J.

Lab Invest. 2014 Jun;94(6):633-44. doi: 10.1038/labinvest.2014.51. Epub 2014 Mar 31.

18.

Angiotensin-induced abdominal aortic aneurysms in hypercholesterolemic mice: role of serum cholesterol and temporal effects of exposure.

Prins PA, Hill MF, Airey D, Nwosu S, Perati PR, Tavori H, F Linton M, Kon V, Fazio S, Sampson UK.

PLoS One. 2014 Jan 23;9(1):e84517. doi: 10.1371/journal.pone.0084517. eCollection 2014.

19.

Chronic kidney disease induced dysfunction of high density lipoprotein.

Yamamoto S, Kon V.

Clin Exp Nephrol. 2014 Apr;18(2):251-4. doi: 10.1007/s10157-013-0857-x. Epub 2013 Sep 10. Review.

20.

Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.

Zuo Y, Chun B, Potthoff SA, Kazi N, Brolin TJ, Orhan D, Yang HC, Ma LJ, Kon V, Myöhänen T, Rhaleb NE, Carretero OA, Fogo AB.

Kidney Int. 2013 Dec;84(6):1166-75. doi: 10.1038/ki.2013.209. Epub 2013 Jun 5.

21.

Importance of high-density lipoprotein quality: evidence from chronic kidney disease.

Kon V, Ikizler TA, Fazio S.

Curr Opin Nephrol Hypertens. 2013 May;22(3):259-65. doi: 10.1097/MNH.0b013e32835fe47f. Review.

22.

Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.

Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V.

J Am Coll Cardiol. 2012 Dec 11;60(23):2372-9. doi: 10.1016/j.jacc.2012.09.013. Epub 2012 Nov 7.

23.

Maturational regression of glomeruli determines the nephron population in normal mice.

Zhong J, Perrien DS, Yang HC, Kon V, Fogo AB, Ichikawa I, Ma J.

Pediatr Res. 2012 Sep;72(3):241-8. doi: 10.1038/pr.2012.81. Epub 2012 Jun 20. Erratum in: Pediatr Res. 2014 Jun;75(6):803.

24.

Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.

Takagi N, Tanizawa T, Kon V, Fogo AB, Ichikawa I, Ma J.

Nephron Extra. 2012 Jan;2(1):17-26. doi: 10.1159/000334961. Epub 2012 Jan 31.

25.

Benzo[a]pyrene potentiates the pathogenesis of abdominal aortic aneurysms in apolipoprotein E knockout mice.

Prins PA, Perati PR, Kon V, Guo Z, Ramesh A, Linton MF, Fazio S, Sampson UK.

Cell Physiol Biochem. 2012;29(1-2):121-30. doi: 10.1159/000337593. Epub 2012 Mar 1.

26.

Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.

Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2856-64. doi: 10.1161/ATVBAHA.111.237198. Epub 2011 Oct 6.

27.

Podocyte injury damages other podocytes.

Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, Ichikawa I.

J Am Soc Nephrol. 2011 Jul;22(7):1275-85. doi: 10.1681/ASN.2010090963. Epub 2011 Jun 30.

28.

Quantitative estimates of the variability of in vivo sonographic measurements of the mouse aorta for studies of abdominal aortic aneurysms and related arterial diseases.

Sampson UK, Perati PR, Prins PA, Pham W, Liu Z, Harrell FE Jr, Linton MF, Gore JC, Kon V, Fazio S.

J Ultrasound Med. 2011 Jun;30(6):773-84.

29.

Protective effects of PPARγ agonist in acute nephrotic syndrome.

Zuo Y, Yang HC, Potthoff SA, Najafian B, Kon V, Ma LJ, Fogo AB.

Nephrol Dial Transplant. 2012 Jan;27(1):174-81. doi: 10.1093/ndt/gfr240. Epub 2011 May 12.

30.

Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside.

Ma J, Matsusaka T, Yang HC, Zhong J, Takagi N, Fogo AB, Kon V, Ichikawa I.

Pediatr Res. 2011 Jul;70(1):83-9. doi: 10.1203/PDR.0b013e31821bdf1c.

31.

Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity.

Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo AB.

Am J Physiol Renal Physiol. 2011 May;300(5):F1203-13. doi: 10.1152/ajprenal.00468.2010. Epub 2011 Mar 2.

32.

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.

Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, Fogo AB, Linton MF, Fazio S, Ichikawa I, Kon V.

Nephrol Dial Transplant. 2011 Aug;26(8):2491-7. doi: 10.1093/ndt/gfq759. Epub 2011 Jan 18.

33.

Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection.

Matsusaka T, Kobayashi K, Kon V, Pastan I, Fogo AB, Ichikawa I.

Am J Physiol Renal Physiol. 2011 Mar;300(3):F792-800. doi: 10.1152/ajprenal.00570.2010. Epub 2010 Dec 22.

34.

Atherosclerosis in chronic kidney disease: the role of macrophages.

Kon V, Linton MF, Fazio S.

Nat Rev Nephrol. 2011 Jan;7(1):45-54. doi: 10.1038/nrneph.2010.157. Epub 2010 Nov 23. Review.

35.

Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients.

Boaz M, Katzir Z, Schwartz D, Gafter U, Biro A, Shtendik L, Kon V, Chernin G, Weinstein T.

Nephron Clin Pract. 2011;117(2):c83-8. doi: 10.1159/000319654. Epub 2010 Aug 6.

PMID:
20714166
36.

The glomerulus--a view from the inside--the endothelial cell.

Fogo AB, Kon V.

Int J Biochem Cell Biol. 2010 Sep;42(9):1388-97. doi: 10.1016/j.biocel.2010.05.015. Epub 2010 Jun 9. Review.

PMID:
20541032
37.

Scope and mechanisms of obesity-related renal disease.

Hunley TE, Ma LJ, Kon V.

Curr Opin Nephrol Hypertens. 2010 May;19(3):227-34. doi: 10.1097/MNH.0b013e3283374c09. Review.

38.

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB.

Am J Physiol Renal Physiol. 2010 Mar;298(3):F683-91. doi: 10.1152/ajprenal.00503.2009. Epub 2009 Dec 30.

39.

Fibrinogen that appears in Bowman's space of proteinuric kidneys in vivo activates podocyte Toll-like receptors 2 and 4 in vitro.

Motojima M, Matsusaka T, Kon V, Ichikawa I.

Nephron Exp Nephrol. 2010;114(2):e39-47. doi: 10.1159/000254390. Epub 2009 Nov 3.

40.

Renal dysfunction potentiates foam cell formation by repressing ABCA1.

Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V.

Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1277-82. doi: 10.1161/ATVBAHA.109.188995. Epub 2009 Aug 10. Erratum in: Arterioscler Thromb Vasc Biol. 2009 Dec 1;29(12):e133. Khan, Wasif [corrected to Khan, Wasif N].

41.

Glomerular filtration: still sympathetic to endothelin's influence?

Hunley TE, Kon V.

J Am Soc Nephrol. 2009 Jul;20(7):1427-9. doi: 10.1681/ASN.2009050503. Epub 2009 Jun 11. No abstract available.

42.

Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.

Yamamoto S, Kon V.

Curr Opin Nephrol Hypertens. 2009 May;18(3):181-8.

43.

Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.

Zhang MZ, Xu J, Yao B, Yin H, Cai Q, Shrubsole MJ, Chen X, Kon V, Zheng W, Pozzi A, Harris RC.

J Clin Invest. 2009 Apr;119(4):876-85. doi: 10.1172/JCI37398. Epub 2009 Mar 23.

44.

Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery.

Fowler SM, Kon V, Ma L, Richards WO, Fogo AB, Hunley TE.

Pediatr Nephrol. 2009 Apr;24(4):851-5. doi: 10.1007/s00467-008-1024-6. Epub 2008 Oct 22.

PMID:
18941798
45.

Myocardial infarction in chronic kidney disease.

Hunley TE, Kon V, Jabs K.

Pediatrics. 2008 Jul;122(1):223-4; author reply 224. doi: 10.1542/peds.2008-0943. No abstract available.

PMID:
18596019
46.

Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.

Suganuma E, Babaev VR, Motojima M, Zuo Y, Ayabe N, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V.

J Am Soc Nephrol. 2007 Aug;18(8):2311-9. Epub 2007 Jul 18.

47.

The renin-angiotensin system in the development of the congenital anomalies of the kidney and urinary tract.

Niimura F, Kon V, Ichikawa I.

Curr Opin Pediatr. 2006 Apr;18(2):161-6. Review.

PMID:
16601496
48.

Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.

Suganuma E, Zuo Y, Ayabe N, Ma J, Babaev VR, Linton MF, Fazio S, Ichikawa I, Fogo AB, Kon V.

J Am Soc Nephrol. 2006 Feb;17(2):433-41. Epub 2005 Dec 21.

49.

Proteomic patterns and prediction of glomerulosclerosis and its mechanisms.

Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB.

J Am Soc Nephrol. 2005 Oct;16(10):2967-75. Epub 2005 Aug 3.

50.

Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice.

Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S, Kon V.

Atherosclerosis. 2006 Feb;184(2):312-21. Epub 2005 Jul 14.

PMID:
16023123

Supplemental Content

Support Center